Region Dermatovenereal Dispensary

Information on the “Uro-Biofon” Apparatus Treatment for Infectious Diseases Transmitted by Sexual contacts.

In all 24 patients have been treated by the “Uro-Biofon” apparatus in combination with antibiotic therapy, among them:

For chlamydiasis – 10 men. On treatment in combination with the “Uro-Biofon”, in the first control chlamydii were not detected for 4 patients. The chlamydii were not detected as well in the second control for one patient. For two patients (20%) the chlamydii were again revealed in the first control. One female did not come for control (10%). The control examination was performed by a microscope.

For ureaplasmosis – 14 men. among them: the analysis for six men (43%) was normal in the first control; for two men it was normal too in the second control as well. For one man it was normal in the third control. For 3 patients ureaplasma was again revealed in the first control. for 5 men – in the process of treatment: cultural diagnosis. 1 patient was taken for gonorrhea treatment without antibiotics. He received six sessions of the Uro-Biofon” radiation, 1 control: by a microscope. Gonorrhea was not diagnosed.

The control group of patients – 30 men, among them:

Patients with chlamydiosis – 12 men. The treatment was conducted without the “Uro-Biofon” application.

For 5 patients chlamydii were not revealed in the first control. It has accounted for 42%.

For 4 patients chlamydii were revealed again. It has amounted for 33%.

For 3 men – in the process of treatment. It has accounted for 25%.

Patients with ureaplasmosis – 18 men.

For 6 men (33%) the ureaplasmosis was not diagnosed in the first control.

For 8 men (45%) the ureaplasmosis was diagnosed again. 4 men (22%) – in the process of treatment.

Despite the small number of patients in the test group and short duration of testing, we can conclude that the good results of the first control analysis due to the “Uro-Biofon” application has accounted for more large percentage: with chlamydia infection – 70%, without the “Uro-Biofon” application – 42%; with ureaplasmosis – 43%, without the “Uro-Biofon” – 33%.

Assistant of head physician T.A.Mamaeva